Skip to contentH
Heron Therapeutics, Inc.
H
HRTXHeron Therapeutics, Inc. Q2 2021 · 10-Q
Revenue$22.44M$22.44M−1.0% vs Q2 2020 Net Income-$61.02M-$61.02MN/M vs Q2 2020 EPS Diluted-$0.62-$0.62N/M vs Q2 2020 Operating Income-$60,469,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Heron Therapeutics, Inc. · CIK 818033 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$63,307,000N/M Margins · derivedOperating margin-269.4%−23.5 pt vs Q2 2020
Net margin-271.9%−28.4 pt vs Q2 2020
ended Jun 30, 2021 · filed Aug 9, 2021 · 40 d after period end